ArticleNMR in biomedicine2026
Magnetic Resonance Spectroscopy of Cystathionine and 2-Hydroxyglutarate in Brain Tumors.
Article in NMR in biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Imaging the hallmarks of cancer.Nature reviews. Cancer · 2026Review
- Magnetic Resonance Spectroscopy of Cystathionine and 2-Hydroxyglutarate in Brain Tumors.NMR in biomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Codeletion of chromosome 1p and 19q arms in a subset of gliomas has been shown to associate with the accumulation of cystathionine in the tumor. Here, we report the analyses of cystathionine and 2-hydroxyglutarate (2HG) in 38 biopsy-proven glioma patients, as measured with TE 97-ms point-resolved spectroscopy (PRESS) at 3 T. Following the confirmation of in-house calculated cystathionine basis signals in a phantom solution, LCModel spectral fitting was performed to decompose metabolite signals, and the millimolar concentrations of metabolites were estimated with reference to water. Cystathionine was estimated to be significantly higher in IDH mutated 1p/19q codeleted gliomas than in noncodeleted gliomas (1.4 ± 1.1 vs. 0.3 ± 0.4 mM; n = 15 and 14; p = 0.002). 2HG estimation was significantly higher in IDH-mutant gliomas compared to IDH-wildtype gliomas (3.7 ± 3.3 vs. 0.1 ± 0.1 mM; n = 29 and 9; p = 0.002). Using cutoff values from receiver operating characteristic curve analysis, the sensitivity and specificity of the cystathionine measures with respect to 1p/19q status were estimated to be 0.8 and 0.79 (cutoff at 0.6 mM), and those of 2HG measures with respect to IDH status were both unity (cutoff at 0.5 mM). A TE 113-ms PRESS sequence was designed to improve detection of the cystathionine C4-proton resonance at 2.72 ppm. Data from two glioma patients showed that cystathionine can be detected with minimal interference from the overlapping aspartate signal. 2D chemical-shift imaging of cystathionine using the TE 113-ms PRESS is demonstrated. Our MRS data confirm elevation of cystathionine in 1p/19q codeleted gliomas, as demonstrated in prior studies, and suggest that relatively high estimates of cystathionine may provide a biomarker of 1p/19q codeleted gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.